All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EDP1815
Therapeutic Area: Dermatology Product Name: EDP1815
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
Advancing EDP1815, its lead anti-inflammatory product candidate, through Phase 2 dose-ranging trials, as well as formulation and manufacturing optimization, towards potential Phase 3 trials in mild to moderate psoriasis and atopic dermatitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EDP1815
Therapeutic Area: Dermatology Product Name: EDP1815
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
Treatment with EDP1815 demonstrates statistically and clinically significant improvement in mean EASI and IGA* BSA scores. EDP1815 first-ever candidate targeting SINTAX™ to show clinical activity in Th1, Th2, and Th17-mediated inflammation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EDP1815
Therapeutic Area: Dermatology Product Name: EDP1815
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
Evelo Biosciences is recruiting ahead of schedule and has completed enrollment of the patients necessary for the interim data readout in the Phase 2 clinical trial evaluating EDP1815 for the treatment of mild to moderate psoriasis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EDP1908
Therapeutic Area: Oncology Product Name: EDP1908
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The data show that orally administered EDP1908 had anti-tumor effects that surpassed both checkpoint inhibitors and orally delivered microbial strains in preclinical models.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EDP1815
Therapeutic Area: Dermatology Product Name: EDP1815
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020
Details:
EDP1815-101 is a double-blind, placebo-controlled Phase 1b trial designed to evaluate the safety and tolerability of EDP1815 in healthy volunteers and patients with psoriasis or atopic dermatitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EDP1815
Therapeutic Area: Dermatology Product Name: EDP1815
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
EDP1815-201 is a double-blind, placebo-controlled, dose-ranging Phase 2 trial designed to evaluate three doses of the enteric capsule formulation of EDP1815 versus placebo in 225 patients with mild to moderate psoriasis over a 16-week treatment period.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EDP1503,Pembrolizumab
Therapeutic Area: Oncology Product Name: EDP1503
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
Details:
An overall response rate (ORR) of 25% (2/8) and a disease control rate of 37.5% (3/8) were observed across all TNBC subjects receiving high dose EDP1503.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EDP1815
Therapeutic Area: Infections and Infectious Diseases Product Name: EDP1815
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $46.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 24, 2020
Details:
The net proceeds from the offering will be used to adavnace existing pipeline including, EDP1815, continue the clinical development of EDP1503, and development activities for additional product candidates, including EDP1867 and EDP2939.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EDP1815,Ambrisentan,Dapagliflozin
Therapeutic Area: Infections and Infectious Diseases Product Name: EDP1815
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
EDP1815 will be included in the TACTIC-E clinical trial. The trial will evaluate the safety and efficacy of certain experimental therapies in the prevention and treatment of life-threatening complications associated with COVID-19 in hospitalized patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EDP1815
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2020
Details:
Phase 2 clinical study is evaluating the safety and efficacy of EDP1815 for the treatment of hospitalized patients with newly diagnosed COVID-19.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
